Epidermolysis Bullosa Pipeline Therapeutics Assessment Report 2024 (Updated)

DelveInsight's, "Epidermolysis Bullosa Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 21+ pipeline drugs in Epidermolysis Bullosa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Epidermolysis Bullosa Research. Learn more about our innovative pipeline today! @ Epidermolysis Bullosa Pipeline Outlook- https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Epidermolysis Bullosa Pipeline Report
• In November 2024:- TWi Biotechnology Inc.- The proposed Phase 2/3 trial with double-blind and open-label extension phases is an international, multicenter study designed to assess the efficacy and safety of diacerein 1% ointment in patients with generalized EBS.
• In November 2024:- Holostem Terapie Avanzate s.r.l.- Prospective, multicenter and multinational, open-label, uncontrolled clinical study to assess the safety and efficacy of autologous cultured epidermal grafts containing epidermal stem cells genetically modified transduced with a LAMB3-gamma retroviral vector. The purpose of this study is to demonstrate the safety and efficacy after one or more treatments with genetically corrected cultured epidermal autograft (Hologene 5) for restoration of the epidermis in patients with generalized intermediate LAMB3-dependent Junctional Epidermolysis Bullosa.
• DelveInsight's Epidermolysis Bullosa pipeline report depicts a robust space with 20+ active players working to develop 21+ pipeline therapies for Epidermolysis Bullosa treatment.
• The leading Epidermolysis Bullosa Companies such as Berg Pharma, Holostem Terapie Avanzate, Aegle Therapeutics, RegeneRx Biopharmaceuticals, BridgeBio Pharma, InMed Pharmaceuticals, Fibrocell Science, Krystal Biotech, and others.
• Promising Epidermolysis Bullosa Therapies such as BPM31510, HOLOGENE-17, AGLE102, RGN-137, PTR-01, INM-755, Dabocemagene autoficel, VYJUVEK, and others.

Stay informed about the cutting-edge advancements in Epidermolysis Bullosa treatments. Download for updates and be a part of the revolution in care @ Epidermolysis Bullosa Clinical Trials Assessment- https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Epidermolysis Bullosa Emerging Drugs Profile

• EB-101: Abeona Therapeutics
EB-101 is an autologous, engineered cell therapy for RDEB, a rare connective tissue disorder without an approved treatment in which patients suffer with severe epidermal wounds that impact the length and quality of their lives. People with RDEB have a defect in the COL7A1 gene, leaving them unable to produce Type VII collagen that helps anchor the dermal and epidermal layers of the skin. In November 2024, Abeona Therapeutics' biologics license application (BLA) for prademagene zamikeracel (pz-cel; EB-101), an investigational autologous gene-corrected epidermal sheet therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa (RDEB), has been accepted for filing by the FDA. The agency has set the Prescription Drug User Fee Act (PDUFA) action date for the BLA for April 29, 2025.

• INM-755: InMed Pharmaceuticals
INM-755 is a cannabinol (CBN) cream intended as a topical therapy to treat symptoms associated with epidermolysis bullosa (EB) and potentially other dermatological diseases. Preclinical data demonstrate that INM-755 (cannabinol) cream may help relieve hallmark EB symptoms, such as pain, inflammation, wound healing and itch, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with Epidermolysis Bullosa.

• BM-3103: BioMendics
The company's lead product in development, BM-3103, is a patented topical gel. It is currently being studied in a Phase I/IIa trial for epidermolysis bullosa simplex, with additional indications in the pipeline. MTORX technology is an investigational platform encompassing therapeutic candidate, BM-3103.

Learn more about Epidermolysis Bullosa Drugs opportunities in our groundbreaking Epidermolysis Bullosa Research and development projects @ Epidermolysis Bullosa Unmet Needs- https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Epidermolysis Bullosa Companies
Berg Pharma, Holostem Terapie Avanzate, Aegle Therapeutics, RegeneRx Biopharmaceuticals, BridgeBio Pharma, InMed Pharmaceuticals, Fibrocell Science, Krystal Biotech, and others.

Epidermolysis bullosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Epidermolysis Bullosa Products have been categorized under various Molecule types such as
• Monoclonal antibody
• Small molecule
• Peptide

Discover the latest advancements in Epidermolysis Bullosa treatment by visiting our website. Stay informed about how we're transforming the future of disease @ Epidermolysis Bullosa Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Epidermolysis Bullosa Pipeline Report
• Coverage- Global
• Epidermolysis Bullosa Companies- Berg Pharma, Holostem Terapie Avanzate, Aegle Therapeutics, RegeneRx Biopharmaceuticals, BridgeBio Pharma, InMed Pharmaceuticals, Fibrocell Science, Krystal Biotech, and others.
• Epidermolysis Bullosa Therapies- BPM31510, HOLOGENE-17, AGLE102, RGN-137, PTR-01, INM-755, Dabocemagene autoficel, VYJUVEK, and others.
• Epidermolysis Bullosa Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Epidermolysis Bullosa Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Epidermolysis Bullosa Pipeline on our website @ Epidermolysis Bullosa Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of content
1. Introduction
2. Executive Summary
3. Epidermolysis bullosa: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. EB-101: Abeona Therapeutics
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. INM-755: InMed Pharmaceuticals
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. Drug name: Company name
14. Drug profiles in the detailed report…..
15. Preclinical and Discovery Stage Products
16. Drug name: Company name
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Epidermolysis bullosa Key Companies
20. Epidermolysis bullosa Key Products
21. Epidermolysis bullosa- Unmet Needs
22. Epidermolysis bullosa- Market Drivers and Barriers
23. Epidermolysis bullosa- Future Perspectives and Conclusion
24. Epidermolysis bullosa Analyst Views
25. Epidermolysis bullosa Key Companies
26. Appendix

List of Highly Demanded Research Reports in 2024

cxcr inhibitors market: https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
fertility monitoring devices market: https://www.delveinsight.com/report-store/fertility-monitoring-devices-fertility-testing-devices-market
ornithine transcarbamylase deficiency market: https://www.delveinsight.com/report-store/ornithine-transcarbamylase-deficiency-otc-deficiency-market
orthopedic power devices market: https://www.delveinsight.com/report-store/orthopedic-power-devices-market
otitis media market: https://www.delveinsight.com/report-store/otitis-media-market
persistent depressive disorder market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
smoking cessation market: https://www.delveinsight.com/report-store/smoking-cessation-market
surgical sealant market: https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
urothelial carcinoma market: https://www.delveinsight.com/report-store/urothelial-carcinoma-market
vascular grafts market: https://www.delveinsight.com/report-store/vascular-grafts-market
vital sign monitors devices market: https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
aplastic anemia market: https://www.delveinsight.com/report-store/aplastic-anemia-market
cart pipeline: https://www.delveinsight.com/report-store/car-t-pipeline-insight
celiac disease market: https://www.delveinsight.com/report-store/celiac-disease-cd-market
coronary stents market: https://www.delveinsight.com/report-store/coronary-stents-market-market
diabetic gastroparesis market: https://www.delveinsight.com/report-store/diabetic-gastroparesis-market-size
elastomeric pump market: https://www.delveinsight.com/report-store/elastomeric-pump-market
friedreich's ataxia market: https://www.delveinsight.com/report-store/friedreichs-ataxia-market
hay fever conjunctivitis market: https://www.delveinsight.com/report-store/hay-fever-conjunctivitis-market
hip replacement devices market: https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
joint reconstruction devices market: https://www.delveinsight.com/report-store/joint-reconstruction-devices-market
periodontal disease market: https://www.delveinsight.com/report-store/periodontal-disease-market
psoriasis vulgaris market: https://www.delveinsight.com/report-store/psoriasis-vulgaris-market
ranibizumab biosimilars market: https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
short bowel syndrome drug market: https://www.delveinsight.com/report-store/short-bowel-syndrome-market
short bowel syndrome market: https://www.delveinsight.com/report-store/short-bowel-syndrome-market
thrombectomy devices market: https://www.delveinsight.com/report-store/thrombectomy-devices-market
type 1 diabetes market: https://www.delveinsight.com/report-store/type-1-diabetes-market
adhd market: https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
attention deficit hyperactivity disorder market: https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
avascular necrosis market: https://www.delveinsight.com/report-store/avascular-necrosis-market
biopsy devices market: https://www.delveinsight.com/report-store/biopsy-devices-market
embolotherapy market: https://www.delveinsight.com/report-store/embolotherapy-market
hydrocephalus treatment market: https://www.delveinsight.com/report-store/hydrocephalus-treatment-market
liquid biospy for cancer diagnostics market: https://www.delveinsight.com/report-store/liquid-biopsy-in-cancer-diagnostics-market
skin grafting devices market: https://www.delveinsight.com/report-store/skin-grafting-devices-market
testicular neoplasm market: https://www.delveinsight.com/report-store/testicular-neoplasm-market
uk healthcare report: https://www.delveinsight.com/report-store/uk-healthcare-outlook-report
vascular access devices market: https://www.delveinsight.com/report-store/vascular-access-device-market
brucellosis market: https://www.delveinsight.com/report-store/brucellosis-market
catheter stabilization devices market: https://www.delveinsight.com/report-store/catheter-stabilization-securement-device-market
dyspepsia market: https://www.delveinsight.com/report-store/functional-dyspepsia-market-share
heart pump devices market: https://www.delveinsight.com/report-store/heart-pump-device-market
phototherapies for psoriasis market: https://www.delveinsight.com/report-store/phototherapies-for-psoriasis-market
radial artery compression device market: https://www.delveinsight.com/report-store/radial-artery-compression-devices-market
sarcopenia market: https://www.delveinsight.com/report-store/sarcopenia-market
shingles market: https://www.delveinsight.com/report-store/shingles-market
surgical site infections market: https://www.delveinsight.com/report-store/surgical-site-infections-ssi-market
venous ulcer market: https://www.delveinsight.com/report-store/venous-leg-ulcer-market
viscosupplementation devices market: https://www.delveinsight.com/report-store/viscosupplementation-devices-market
artificial disc market: https://www.delveinsight.com/report-store/artificial-disc-market
healthcare consulting solutions: https://www.delveinsight.com/consulting
meningococcal meningitis market: https://www.delveinsight.com/report-store/meningococcal-meningitis-market
moderate to severe plaque psoriasis market: https://www.delveinsight.com/blog/us-psoriasis-treatment
pertussis market: https://www.delveinsight.com/report-store/pertussis-market
spinal trauma devices market: https://www.delveinsight.com/report-store/spinal-trauma-devices-market-market
surgical energy instruments market: https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
temporomandibular disorders market: https://www.delveinsight.com/report-store/temporomandibular-disorders-market
transcatheter heart valve replacement devices market: https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market
urinary catheters market: https://www.delveinsight.com/report-store/urinary-catheters-market
attention deficit hyperactivity disorder adhd market: https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
coronary angioplasty market: https://www.delveinsight.com/report-store/coronary-stents-market-market
nonalcoholic steatohepatitis market: https://www.delveinsight.com/report-store/nonalcoholic-steatohepatitis-nash-market
orthopedic splints device market: https://www.delveinsight.com/report-store/orthopedic-splints-market
perennial allergic rhinitis market: https://www.delveinsight.com/report-store/perennial-allergic-rhinitis-market
pipeline assessment services: https://www.delveinsight.com/consulting/pipeline-assessment-services
schistosomiasis market: https://www.delveinsight.com/report-store/schistosomiasis-market
venous thromboembolism market: https://www.delveinsight.com/report-store/venous-thromboembolism-market
bacterial meningitis market: https://www.delveinsight.com/report-store/meningococcal-meningitis-market
nk cell therapy market: https://www.delveinsight.com/report-store/nk-cell-therapy-market
overactive bladder syndrome market: https://www.delveinsight.com/report-store/overactive-bladder-market
peripheral nerve injuries market: https://www.delveinsight.com/report-store/peripheral-nerve-injuries-market
tendonitis market: https://www.delveinsight.com/report-store/tendonitis-market
endoscopic ultrasound market: https://www.delveinsight.com/report-store/endoscopic-ultrasound-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.